Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis.

IF 4.9 2区 医学 Q1 OPHTHALMOLOGY
Ngozi C Chidi-Egboka, Leo Fan, Maria Qureshi, Chameen Samarawickrama, Fiona Stapleton, Tanya Trinh, Maria Markoulli, Elsie Chan, Jern Yee Chen, Jason Holland, Stephanie L Watson
{"title":"Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis.","authors":"Ngozi C Chidi-Egboka, Leo Fan, Maria Qureshi, Chameen Samarawickrama, Fiona Stapleton, Tanya Trinh, Maria Markoulli, Elsie Chan, Jern Yee Chen, Jason Holland, Stephanie L Watson","doi":"10.1111/ceo.14514","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To identify evidence on the use of topical CsA for ocular surface diseases (OSD).</p><p><strong>Methods: </strong>A literature search was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) through June 2023 via Cochrane Central Registries, Clinical Trials Registry, Grey literature and citation searching. Randomised clinical trials (RCTs) in which different concentrations of topical CsA were compared with one another or other topical therapies were included. Risk of bias was assessed following the Cochrane ROB2 standard tool. Meta-analysis was considered when data were sufficient. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE).</p><p><strong>Results: </strong>Five hundred and eight-three RCT publication titles were identified, of which 48 OSD RCTs were included. Thirty trials found significantly better efficacy with CsA irrespective of dose or concentration for OSD. The effect of CsA was comparable to artificial tears (AT), vehicle, fluorometholone 0.1%, tacrolimus 0.03% or diquafosol 3% only in 13 trials. Improved outcomes with CsA for symptoms (RCTs comprising 1107-patients) and clinical signs, including in ocular surface staining (2505-patients) and the average number of goblet cells (138-patients) were found. Inconsistency of treatment effect on symptoms and signs, particularly tear film function, was evident in some trials. Ten trials were judged to be at high risk of bias. The certainty of evidence was judged to be low to moderate, downgraded mostly for imprecision and risk of bias.</p><p><strong>Conclusions: </strong>Topical CsA treatment effect on ocular surface symptoms and staining suggests that CsA may be superior to the vehicle, AT or other topical treatment alternatives for OSD.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ceo.14514","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To identify evidence on the use of topical CsA for ocular surface diseases (OSD).

Methods: A literature search was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) through June 2023 via Cochrane Central Registries, Clinical Trials Registry, Grey literature and citation searching. Randomised clinical trials (RCTs) in which different concentrations of topical CsA were compared with one another or other topical therapies were included. Risk of bias was assessed following the Cochrane ROB2 standard tool. Meta-analysis was considered when data were sufficient. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE).

Results: Five hundred and eight-three RCT publication titles were identified, of which 48 OSD RCTs were included. Thirty trials found significantly better efficacy with CsA irrespective of dose or concentration for OSD. The effect of CsA was comparable to artificial tears (AT), vehicle, fluorometholone 0.1%, tacrolimus 0.03% or diquafosol 3% only in 13 trials. Improved outcomes with CsA for symptoms (RCTs comprising 1107-patients) and clinical signs, including in ocular surface staining (2505-patients) and the average number of goblet cells (138-patients) were found. Inconsistency of treatment effect on symptoms and signs, particularly tear film function, was evident in some trials. Ten trials were judged to be at high risk of bias. The certainty of evidence was judged to be low to moderate, downgraded mostly for imprecision and risk of bias.

Conclusions: Topical CsA treatment effect on ocular surface symptoms and staining suggests that CsA may be superior to the vehicle, AT or other topical treatment alternatives for OSD.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.60
自引率
12.50%
发文量
150
审稿时长
4-8 weeks
期刊介绍: Clinical & Experimental Ophthalmology is the official journal of The Royal Australian and New Zealand College of Ophthalmologists. The journal publishes peer-reviewed original research and reviews dealing with all aspects of clinical practice and research which are international in scope and application. CEO recognises the importance of collaborative research and welcomes papers that have a direct influence on ophthalmic practice but are not unique to ophthalmology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信